





# Year 3 Case-based Learning 2024-2025 Case 1 Part 2 Facilitator Materials



**Key Contributors:** 

Michael Trimble – Academic Lead for Year 3 CBL

Amy Taylor – ADEPT Fellow 2021-22

# Contents

STUDENT MATERIALS	3
Surgical Outpatient Clinic Letter	3
Surgical Admission Document	4
Consent form	8
Operation Note	14
Histopathology	18
Day 3 post-op	20
F1 Urgent Review	20
Kardex	22
Investigations	34
Complete Blood Count	34
Electrolyte Profile	34
Liver Profile	35
CRP	35
D dimer	35
NT pro-BNP	36
Troponin T	36
ABG	37
ECG	38
Chest X-ray	39
ADDITIONAL MATERIALS FOR FACILITATED SESSION	40
Specialty Trainee Review	40
Investigations	44
CTPA	44
STUDENT MATERIALS	46
NEWS Observation Chart	46

# STUDENT MATERIALS

# Surgical Outpatient Clinic Letter

Eastside Medical Practice
Bracton Terrace
Belfast
3 <sup>rd</sup> October 2022
Dear Dr Denniston,
RE: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place
Your patient was reviewed at the surgical outpatient clinic today, on a red flag basis. She had a
recent admission under our medical colleagues for altered bowel habit. She was found to have a right sided colonic adenocarcinoma with associated anaemia. Further imaging revealed no distant
metastases. She was discussed at our regional colorectal MDT and it was agreed that surgical
intervention is appropriate. She received treatment for iron deficiency anaemia during her stay.
Mrs Bibi has remained well since discharge but is suffering from ongoing diarrhoea which she describes as nearly black in colour. She has been eating and drinking small amounts but describes
ongoing weight loss.
She is usually fit and well. She doesn't work and is fully independent. She has hypertension, for
which she takes Ramipril, and has never had any abdominal surgery. On examination today, her abdomen is soft and non-tender and there are no masses palpable. There are no scars.
I have had a long discussion today with Mrs Bibi about the indication for surgery and the expected
peri-operative course. We have discussed the risks of surgery in general and the risks specific to a
laparoscopic right hemicolectomy. She is keen to proceed. She will meet our colorectal specialist nurse today who will explore options for psychosocial support.
I will make arrangements for her admission, which will likely be next week.
i will make all aligements for her aumission, which will likely be flext week.
Yours sincerely,
Ms Nicola Stapleton
Consultant Colorectal Surgeon

# Surgical Admission Document

Insert G.P.'s Name and Address if not included on request letter or admission form	CLINICAL NOTES  ENTER A Mit/s/Miss & A: Farah Bibi :D  Address C Consultant & Ward/Clinic D Hospial No. E S M. or W F Date of Birth G Occupation In Patient Admn Date C: 14 St Anne's Place :H  EACH ENTRY TO BE DATED AND SIGNED  Diagnosis  11.10.2022: Surgical admission O8.00  A. COMMORS, Surgical FYI  CONSUltant: Miss Stapleton
(	PC: Elective admission for Laparoscopic Right Hemicolectomy
PITAL	PMH: Hypertension, osteoarthritis
AL VICTORIA HOSP BELFAST, BT12 6BA	Allergies: Penicillin - rash
ROYAL VICTORIA HOSPITAL BELFAST, BT12 6BA	Drugs: Ramipril 10mg MANE Paracetamol 1g PRN
Ţ.	Family history: Sister-UC Brother-Colon Ca (RIP)
	Social history: Lives with daughter
	Non-smoker Fully independent
	Alcohol screen: Nil
Form No	
M 100 (A S 7)	WFH000273 Revised 10/12 OS1214

Text:

Patient: Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place

Consultant: Stapleton Admitting Doctor: A. Connors Designation: FY1

Date: 11/10/2022

Time: 08:00

Presenting Complaint: Elective Admission for Laparoscopic Right Hemicolectomy

Past Medical History: Hypertension, Osteoarthritis

Allergy Status: Possibly had rash with penicillin as a child

Medication: Ramipril 10mg mane

Paracetamol PRN

Family History: Sister: UC

**Brother: Colon Cancer** 

Social History: Widow, non-smoker, lives with daughter

Fully independent.

Alcohol Screening: Nil

0/E RR 16	Pulse 65
Temp 36.6°C	A BP 125/68 BM 6.9
Spor 99% R Temp 36.6°C (AVPN 6CS 15/15	Weight 54/cg
Looks well, muco	us membranes slightly
HS1 + 11 + 0	JVP not visible, nil oeder
Tro Ex N'i	pansion equal added sounds
2	S +
For theatre toda	ay
	a Connorn Fy

#### Text:

O/E: RR 16, SpO2 (99% RA, Pulse 65, BP 125/68, AVPU A, Temp 36.6, BM 6.9, weight 54Kg, GCS

15/15.

General Examination: Looks well, slightly dry mucus membranes

Cardiovascular Examination: HS I + II + nil, JVP not visible, no oedema

Respiratory Examination:

Trachea central, expansion equal, resonant to percussion, breath

sounds vesicular, nil added

Gastrointestinal Examination: Abdomen soft, non tender

Diagnosis / Differential: For theatre today

Management Plan: Admit

Signed A Connors FY1

#### Consent form

#### FORM 1

#### **CONSENT FOR EXAMINATION, TREATMENT OR CARE**

# WHEN COMPLETING THIS FORM PLEASE ENSURE THAT IT IS OPEN FLAT ON A HARD SURFACE

#### PRESS FIRMLY WITH BALLPOINT PEN ONLY

#### Guidance to healthcare professionals

#### What a consent form is for

This form documents the person's agreement to go ahead with the investigation or treatment you have proposed. It is not a legal waiver - if individuals, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. They are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoire, by providing a check-list of the kind of information which should be offered, and by enabling the person to have a written record of the main points discussed. In no way, however, should the written information provided be regarded as a substitute for face-to-face discussions.

#### The law on Consent

See the Department of Health, Social Services and Public Safety publication Reference Guide to Consent for Examination, Treatment or Care for a comprehensive summary of the law on consent (also available at <a href="https://www.dhsspsni.gov.uk">www.dhsspsni.gov.uk</a>).

#### Who can give consent

Everyone aged 16 or more is presumed to be competent to give consent for themselves, unless the opposite is demonstrated. If a child under the age of 16 has "sufficient understanding and intelligence to enable him or her to understand fully what is proposed", then he or she will be competent to give consent for himself or herself. Young people aged 16 and 17, and legally 'competent' younger children, may therefore sign this form for themselves, but may like a parent to countersign as well. If the child is not able to give consent for himself or herself, someone with parental responsibility may do so on their behalf and a separate form (Form 2) is available for this purpose. Even when a child is able to give consent for himself or herself, you should always involve those with parental responsibility in the child's care, unless the child specifically asks you not to do so. If an individual is mentally competent to give consent but is physically unable to sign a form, you should complete this form as usual, and ask an independent witness to confirm that s/he has given consent orally or non-verbally.

#### When NOT to use this form

If the person is 18 or over and is not legally competent to give consent, you should use form 4 (form for adults who are unable to consent to investigation or treatment) instead of this form. A person will not be legally competent to give consent if:

- s/he is unable to comprehend and retain information material to the decision and/or
- s/he is unable to weigh and use this information in coming to a decision.

You should always take all reasonable steps (for example involving more specialist colleagues) to support an individual in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign this form on behalf of an adult who is not legally competent to consent for himself or herself.

#### Information

Information about what treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for people when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'serious or frequently occurring' risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, people may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that they receive at least very basic information about what is proposed. Where information is refused, you should document this on the form and in the case notes.



An Roinn Sláinte, Seirbhísí Sóisialta agus Sábháilteachta Poiblí

www.dhsspsni.gov.uk

May 2006

#### Text:

FORM 1 CONSENT FOR EXAM

CONSENT FOR EXAMINATION, TREATMENT OR CARE WHEN COMPLETING THIS FORM PLEASE ENSURE THAT IT IS OPEN FLAT ON A HARD SURFACE

PRESS FIRMLY WITH BALLPOINT PEN ONLY

PRESS FIRMLY WITH BALLPOINT PEN UNL

Guidance to healthcare professionals

What a consent form is for

This form documents the person's agreement to go ahead with the investigation or treatment you have proposed. It is not a legal waiver - if individuals. for example, do not receive enough information on which to base their decision. then the consent may not be valid, even though the form has been signed. 'They are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aide-memoire, by providing a check-list of the kind of information which should be offered, and by enabling the person to have a written record of the main points discussed. In no way, however, should the written information provided be regarded as a substitute for face-to-face discussions.

The law on Consent

See the Department of Health, Social Services and Public Safety publication Reference Guide to Consent for Examination, Treatment or Care for a comprehensive summary of the law on consent (also available at www.dhsspsni.go.y.lrlk).

Who can give consent

Everyone aged 16 or more is presumed to be competent to give consent for themselves, unless the opposite is demonstrated. If a child under the age of 16 has "sufficient understanding and intelligence to enable him or her to understand fully what is proposed", then he or she will be competent to give consent for himself or herself. Young people aged 16 and 17. and legally 'competent' younger children, may therefore sign this form for themselves, but may like a parent to countersign as well. If the child is not able to give consent for himself or herself, someone with parental responsibility may do so on their behalf and a separate form (Form 2) is available for this purpose. Even when a child is able to give consent for himself or herself, you should always involve those with parental responsibility in the child's care, unless the child specifically asks you not to do so. If an individual is mentally competent to give consent but is physically unable to sign a form, you should complete this form as usual, and ask an independent witness to confirm that s/he has given consent orally or non-verbally.

When NOT to use this form

If the person is 18 or over and is not legally competent to give consent, you should use form 4 (form for adults who are unable to consent to investigation or treatment) instead of this form. A person will not be legally competent to give consent if:

- s/he is unable to comprehend and retain information material to the decision and/or
- s/he is unable to weigh and use this information in coming to a decision.

You should always take all reasonable steps (for example involving more specialist colleagues) to support an individual in making their own decision, before concluding that they are unable to do so. Relatives cannot be asked to sign this form on behalf of an adult who is not legally competent to consent for himself or herself. Information

Information about what treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for people when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'serious or frequently occurring' risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, people may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that they receive at least very basic information about what is proposed. Where information is refused, you should document this on the form and in the case notes. Health, Social Services and Public Safety An Roinn Slåinte, Seirbhfsi Söisialta

HSS TRUST	GP PRACTICE or other			
Hospital Unit	Primary Care Provider			
FORM 1 - CONSENT FOR EXAMINATION, TREATMENT OR CARE				
Personal details (or pre-printed label)				
Surname/family name  First names  Date of Birth  Male Dr. Female H+C No. (or other identifier)  Special requirements (language or other)	2 035 7027 reter used with consent			
Statement of healthcare professional				
Responsible healthcare professional	t (include side of body or site and brief explanation if medical term not clear)			
The intended benefits Removal of rolen	Lander			
Serious or frequently occurring risks	Munitary e necessary during the procedure. pecify)			
I have also discussed what the procedure is lift available alternative treatments (including no t taken and any particular concerns of this indiv	reatment), any samples of tissue that may be			
$\hfill \Box$ The following leaflet/tape has been provided				
Signed J. Dullar Name (Print) STILLON	Date 11/10/22 Job Title General Lungery 575			
Contact details (if patient wishes to discuss options later)				
Statement of interpr	eter (where appropriate)			
I have interpreted the information above to the pe in a way which I believe s/he can understand.  Signed Signed Akter  Name (Print) Snamin Akter	Date			
Copy accepted by person giving conser	nt Yes/No (please circle)			

#### Text:

Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place

Female

Consultant: Ms N Stapleton

Name of Proposed Procedure: Laparoscopic Right Hemicolectomy +/- open

I have explained the procedure, in particular I have explained:

The intended Benefits: Removal of Colon Cancer

#### INTERPRETER USED WITH CONSENT

Serious or frequently occurring risks: Bleeding, Infection, Collection, Conversion to Open, Damage to surrounding structures, Ureteric Injury, Anastomotic leak, Stoma, Further surgery, DVT, PE, Pneumonia.

Possible additional procedures which may become necessary: Blood Transfusion, Ileostomy

The procedure will involve general and/or regional anaesthesia

Signed by Healthcare Practitioner: J. Dillon, 11/10/22

Job Title: General Surgery ST5

Statement of interpreter: I have interpreted the information above to the person giving consent to the best of my ability and in a way which I believe s/he can understand.

Signed Sharmin Akter 11/10/22

# Statement of person giving consent

Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask - we are here to help you. You have the right to change your mind at any time, including after you have signed the form.
I agree to the procedure or course of treatment described on this form.
I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate experience.
I understand that I will have the opportunity to discuss the details of anaesthesia with an anaesthetist before the procedure, unless the urgency of my situation prevents this. (This only applies to patients having general or regional anaesthesia).
I understand that any procedure in addition to those described on this form will only be carried out if it is necessary to save my life or to prevent serious harm to my health.
I have been told about possible additional procedures which may become necessary during my treatment.  I have listed below any procedures which I do not wish to be carried out without further discussion.
······································
*I agree that healthcare students, who will be supervised by healthcare professionals, may observe or assist in my care. * You may remove this sentence without affecting your care.
Signature Date N.10.22
Name (Print) Farah Bibi
A witness should sign below if the person is unable to sign but has indicated his or her consent. Young people/children may also like a parent to sign here (see notes)
Signature Date
Name (Print)
Confirmation of consent (to be completed by a healthcare professional when the person is admitted for the procedure, if s/he has signed the form in advance). I have confirmed that s/he has no further questions and wishes the procedure to go ahead.
SignatureDate
Name (Print)
Important notes: (tick if applicable)
See also advance directive/living will (eg Jehovah's Witness form)
Person has withdrawn consent
LPC 03/09/031 Web Version Oct 11 WPH000035

Web Version Oct 11 WPH000035

#### Text:

Statement of person giving consent

Please read this form carefully. If your treatment has been planned in advance, you should already have your own copy which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask - we are here to help you. You have the right to change your mind at any time, including after you have signed the form.

I agree to the procedure or course of treatment described on this form.

I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate experience.

I understand that I will have the opportunity to discuss the details of anaesthesia with an anaesthetist before the procedure, unless the urgency of my situation prevents this. (This only applies to patients having general or regional anaesthesia).

I understand that any procedure in addition to those described on this form will only be carried out if it is necessary to save my life or to prevent serious harm to my health.

I have been told about possible additional procedures which may become necessary during my treatment.

I have listed below any procedures which I do not wish to be carried out without further discussion.

\*I agree that healthcare students, who will be supervised by healthcare professionals, may observe or assist in my care. \* You may remove this sentence without affecting your care.

Signature Farah Bibi, Name (Print) Farah Bibi, Date 11/10/22

A witness should sign below if the person is unable to sign but has indicated his or her consent.

Young people/children may also like a parent to sign here (see notes)

Signature...... Name (Print)...... Date ......

Confirmation Of consent (to be completed by a healthcare professional when the person is admitted for the procedure, if s/he has signed the form in advance). I have confirmed that s/he has no further questions and wishes the procedure to go ahead.

Signature Name (Print) Job titleDate	Signature	Name (Print)	Date	
--------------------------------------	-----------	--------------	------	--

Important notes: (tick if applicable)

See also advance directive/living will (eg Jehovah's Witness form)

# Operation Note

Oper	ration Notes
Name Farah Buri  Address 14 St Janu's Bace  Bellost  DOB 11 / 10 / 22  Male Female  Hospital No. 412 035 7027  Consultant in charge Man N. Star  Consultant anaesthetist in charge 1.	Fill in patient details opposite or affix ID label here
Operation Notes	
Theatre Surgeon 1st assistant 2nd assistant	Date \\\/\langle \/\langle \\/\langle \\\/\langle \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Procedure  Laparopropia R	ight Hemiolestons
	e overleaf if required)
Laparomopia R  Operative details and diagrams (continue	e overleaf if required)
Laparomopia R  Operative details and diagrams (continue	e overleaf if required)
Laparomopia R  Operative details and diagrams (continue	e overleaf if required)
Laparopropie R  Operative details and diagrams (continue  General anaesthetic  Antibiotius given  Wrianz catheter invert	e overleaf if required)
Departive details and diagrams (continue general ancienthetic Antibiotics given the wary catheter invert Infraumblical incision	e overleaf if required)
Derative details and diagrams (continue general ancienthetic Antibiotics given the inverted and incision 12 mm port inverted a	e overleaf if required)  Ed  at umbilias
Derative details and diagrams (continue general anaesthetic Antibiotics given the west Infraumblical incision 12 mm port inserted anaesthetic green by	e overleaf if required)  Ed  at umbilias  y Harron technique
Departive details and diagrams (continue)  General ancienthetic  Antibiotius given  Urianz catheter invert  Infraumblical incircon  12 mm port inverted  Preumoperitoneum by  12mm + Smm ports	e overleaf if required)  Ed  at umbilias

#### Text:

**Operation Notes** 

Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place

Date 11/10/2022

Consultant Responsible: Ms N Stapleton

Consultant anaesthetist: L. McKane

Operation notes

Theatre 1, date 11/10/22, Surgeon: Ms J Dillon ST5, Assistant: Stapleton

Scrub nurse: S Philips

Procedure: Laparoscopic Right Hemicolectomy

Operation details and diagrams:

**General Anaesthetic** 

Antibiotics given

Urinary catheter inserted

Infraumbilical incision

12mm port inserted at umbilicus

Pneumoperitoneum by Hasson technique

12mm and 5mm ports placed under direct vision

Ileocolic pedicle identified and medial mobilization carried out

Duodenum visualised and protected

# Operative details and diagrams (continued) Hem-o-lok × 3 to ilevolic artery + divided , 2 clips to remain Lateral motidisation to hepatic flexure Thepatic flaure fully mobilized + right branch of middle colic artery preserved Midline wound extended Specimen resected + removed Side - to-ride anaxtomonis formed using TLC 75 + TA 90 and overnewed Closure Drains Yes/No (if yes record size)

1/10

Post-operative instructions

Signature J Dillon ST

Enhanced recovery. Eat + drink. bortime clexare.
Mobilise from tomorrow. batheter out when mobile.
IV pluids down tomorrow if drinking.

lext:
Operative details and diagrams (continued)
Hemo-o-lok x 3 to ileocolic artery and divided, two clips to remain
Lateral mobilization to hepatic flexure
Hepatic flexure fully mobilised and right branch of middle colic artery preserved
Midline wound extended
Specimen resected and removed
Side to side anastomosis formed using TLC 75 and TA 90 and oversewed
Closure
J-Vicryl to umbilicus, 3.0 monocryl to skin
Drains
No
Post-operative instructions
Enhanced recovery
Eat and drink
Continue clexane
Mobilise from tomorrow
Catheter out when mobile
IV Fluids down tomorrow if drinking
Signature J Dillon

# Histopathology

**CLINICAL DETAILS** 

Bulky caecal tumour. Laparoscopic right hemicolectomy.

PATHOLOGIST'S REPORT

**GROSS DESCRIPTION** 

TYPE OF SPECIMEN: Right hemicolectomy

SITE OF TUMOUR: Caecum

LENGTH OF SPECIMEN: 140mm terminal ileum,170 mm caecum / ascending colon, 70 mm appendix


MAXIMUM TUMOUR DIAMETER: 65 mm

NATURE OF TUMOUR: Polypoid

TUMOUR PERFORATION: No

DISTANCE OF TUMOUR FROM NEAREST CUT END: Distal 110mm

#### **HISTOLOGY**



#### Click HERE to view digital slide

HISTOLOGICAL TYPE: Adenocarcinoma

DIFFERENTIATION: Moderately differentiated

LOCAL INVASION (TNM8): pT3


MAXIMUM DISTANCE OF SPREAD BEYOND MUSCULARIS PROPRIA: 5 mm

DEEPEST LEVEL OF VENOUS INVASION: None

DEEPEST LEVEL OF LYMPHATIC INVASION: Extramural- block B4

DEEPEST LEVEL OF PERINEURAL INVASION: None

#### LYMPH NODES:



#### Click HERE to view digital slide

Number identified: 21

Infiltrated by tumour: 0

APICAL NODE: Not Involved

NUMBER OF TUMOUR DEPOSITS: None

PERITONEAL INVOLVEMENT: Not seen - see comments

PROXIMAL MARGIN: Not involved

**DISTAL MARGIN: Not involved** 

NON-PERITONEALISED CIRCUMFERENTIAL MARGIN: Not involved

HISTOLOGICAL MEASUREMENT FROM TUMOUR TO NON-PERITONEALISED MARGIN: 1.3mm

PREOPERATIVE THERAPY GIVEN: No

PREOPERATIVE THERAPY RESPONSE: Not applicable

HISTOLOGICALLY CONFIRMED METASTATIC DISEASE: No

pTNM8 STAGING: pT3N0

COMPLETE RESECTION: Yes (R0)

#### **DIAGNOSIS**

**CAECUM** 

ADENOCARCINOMA

LYMPH NODES

**NEGATIVE FOR TUMOUR** 

# Day 3 post-op

Mrs Bibi is recovering on the surgical ward. IV fluids have been stopped, catheter has been removed and she is tolerating a light diet. Her pain was initially controlled with a PCA but she is now on oral analgesia. The F1 on the ward has been asked to see her urgently as she has developed chest pain and shortness of breath.

# F1 Urgent Review

Insert G.P.'s Name and Address if not included on request letter or admission form	CLINICAL NOTES  ENTER Full Name A Ministrilis & A: B Address Consultant & WardCollinic D Hospital No. E SM or VI. F Date of Birth G Occupation H In-Patient In-Patient D Hospital No. C: L4 St AMNe'S PLACE :H  EACH ENTRY TO BE DATED AND SIGNED  Diagnosis  14. 10. 22  ATS P (e. USQ)
ROYAL VICTORIA HOSPITAL BELFAST, BT12 6BA	D3 Lap R hemicolectomy  Sudden onset chest pain on breathing in t  SOB @ 13.15. Obs checked + sats L  O2 applied > sats T. Attended immediately.  A - Patent  B - RR 30. SoDo 92% on 40% Oo
BE	JA/E Some scattered creps  C - Pulse 126 bpm CRT < 2s Bl 130/80 ECG - Sinus tachy  D - GCS 15/15
Form No M 100 (R S 7)	E - Temp 37.5  Imp:  Plan:  Q (OMON FX)  WPH000273 Revised 10/12  # 44.84 OS12147

Text:
Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place
14/10/22 13.30 Connors F1 - urgent review
ATSP re. reduced sats
D3 Laparoscopic Right Hemicolectomy
Sudden onset chest pain on breathing in and SOB at 13.15. Obs checked and sats reduced, increased when O2 applied. Attended immediately.
A – Patent
B – RR 30, Sao2 92% on 40%v O2, chest examination – reduced air entry, some scattered creps
C – Pulse 126, BP 130/80, CRT <2s, ECG – sinus tachy
D – GCS 15/15
E – Temp 37.5
Impression:
P:
Signed Connors F1

# Kardex

Administration	on R	ecord	Rewritten on ( Rewrite check		
Allergies / Medicine sensit This section must be completed before prescribin except in exceptional circumstances  Date of Reaction Medicine/allergen Type of reaction (eg. rash)  Penicillin Type of reaction (eg. rash)	ng and adn	ninistration	Surname: BIP First names: FAR Health and Care no: L	AH	or use addressograph  35 7027
Or  No known allergies (Please tick) Signature / Designation:	Date:		Hospital: RV N Consultant: STAPLET ( Date Weight	J VV	Ward: SURGER Date of admission: 11-10-2 Height BSA
Risk factors that may require consideration for dose adjustment and medicine choice  Signature:  Date:  Additional charts in use (tick each chart) Other prescription charts in use must be referenced on the Prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is no low the prescription and Administration Record. If a chart is not low the prescription and Administration Record. If a chart is not low the prescription and the prescription and the prescription and the prescription and the	) ne main presonger in use,  Fluid b	put a line through	the selected box below and da	ne Medicine e and sign etetic	Common abbreviations routes of administration Buccal Buccal Inhalations INH Intramuscular IM Intravenous IV Nasogastric NG Nebulised NEB Oral PC Per gastrostomy PEG Per rectum PR Subcutaneous SC Sublingual SL Topical Transdermal TD Vaginal PC
				e: 11/10,	Abbreviations for freque
Codes for recording omitted doses Rei  1 = Nil by mouth 2 = Patient refused 3 = Patient not available and availabl	vailable	yed or omitted  (5) = Vomitin  (6) = Drug n	ng 🗇 = Other	(Record	on pg.13) rs for each dose to be withheld
For guidelines on presonable Additional notes on medicines  (For example, any medicines withheld on or during the formula of t					
	Sr.				
Contents	Page	Contents		Page	
Contents  VTE risk assessment  Anticoagulant/antiplatelet medicines (All routes)  Initial antimicrobial medication (All routes)	Page 2 3 4	Regular injecta	ible medication	Page 6-7 8-12 13	Contents Pa As required medication 14- Once only medicines and pre-medication 1

#### Text:

Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place

Allergy – penicillin (rash as a child)

Surgical ward, Consultant Stapleton, date of admission 11/10/22

Medication history source ECR

Ramipril 10mg OD ON HOLD

# <sup>2</sup> Venous Thromboembolism (VTE) **Risk Assessment for Hospitalised**

Patient Name:	F	ARAV	4 B	(B)		
H&C Number.:				-	Age	64

Step 1: Assess for level of mobility	- All patie	nts				
Tick			Tick		*	Tick
Surgical patient Media	Medical patient expected to have ongoing reduced mobility relative to normal state				Medical patient NOT expected to have significantly reduced mobility relative to normal state	
Assess for thrombosis and bleeding risk below (Comp	lete steps 2 – 5)			Risk asses	sment complete (Go to step 5)	
Step 2: Review thrombosis risk  Any tick for thrombosis risk factors should	prompt consid	doration for	thromb	onronh	vlavis	
Patient related			k Admission related		Tick	
Active cancer or cancer treatment	L.	,	Significantly reduced mobility for 3 days or more			
age >60		Hip or kn	,		.,	
Dehydration		/ Hip fractu				
(nown thrombophilias				+ surgery	time > 90 minutes	1
Personal history/first degree relative with history of V	Œ				lower limb with	
One or more significant medical comorbidities (eg. he					>60 minutes	
netabolic, endocrine or respiratory pathologies; acute diseases; inflammatory conditions)		Acute sur intra-abd			th inflammatory or	
Obesity (BMI >30kg/m²)		Critical ca	are admis	ssion		
Jse of hormone replacement therapy		Surgery v	vith sign	ificant rec	luction in mobility	
Jse of oestrogen-containing oral contraceptive thera	ру				not exhaustive, additional risks may be	
/aricose veins with phlebitis		considere	ed. Other	r:		
Pregnancy or <6 weeks post partum						
(see obstetric risk assessment for VTE)						
Step 3: Review bleeding risk						
Any tick should prompt staff to consider if	bleeding risk	is sufficient	to pred	clude ph	armacological intervention	
Patient related			Admission related			Tick
Active bleeding		Neurosur	gery, spi	inal surge	ry or eye surgery	
Acquired bleeding disorder (such as acute liver failure	2)	Lumbar p 12 hours		/epidural	spinal anaesthesia expected in the next	
Concurrent use of anticoagulants known to increase bleeding (such as warfarin with INR >2 or DOAC/NC apixaban, dabigatran, edoxaban or rivaroxaban)		Lumbar p hours	ouncture	/epidural	spinal anaesthesia within the previous 4	
Acute stroke		Other pro	ocedure	with high	bleeding risk	
Thrombocytopaenia (Platelets <75x109/l)		The abov	e risk fa	ctors are	not exhaustive, additional risks may be	
		consider	ed. Othe	r:		
Uncontrolled hypertension (>230/120mmHa)						
Untreated inherited bleeding disorder (such as						
	ategory					
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk	category			Tick		Tick
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk (	category	High risk of \	/TE with	Tick		Tick
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk		High risk of \significant blee			Low risk of VTE	Tick
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk of the high risk of VTE with		significant blee	ding risk		Low risk of VTE Pharmacological eg. LMWH	
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk (  Tick  Risk of VTE High risk of VTE with low bleeding risk		significant blee				
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk of the such as haemophilia and von Willebrand's disease)  Tick Risk of VTE High risk of VTE with low bleeding risk of the such appropriate risk of the su		significant blee	ding risk		Pharmacological eg. LMWH	
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk of the control of	Š	significant blee	ding risk		Pharmacological eg. LMWH nical eg. Antiembolic compression hosiery	
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk of the such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk of the such as haemophilia and von Willebrand's disease)  Tick Tick Tick Tick Tick Tick Tick Tick		significant blee	escribed Print	Mecha	Pharmacological eg. LMWH	
Untreated inherited bleeding disorder (such as haemophilia and von Willebrand's disease)  Step 4: Tick the appropriate risk of the control of	1MAM) 12 TI	significant blee Type pr	Print	Mecha	Pharmacological eg. LMWH nical eg. Antiembolic compression hosiery  A. ONNOCS	

#### Text:

Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place

Step 1 – Assess for level of mobility – All patients

Surgical patient

Step 2 – Review thrombosis list

Active cancer or cancer treatment, age >60, dehydration, total anaesthetic and surgery time >90mins

Step 3 – Review bleeding risk

Step 4 – Tick the appropriate risk category

High risk of VTE with low bleeding risk


Is thromboprophylaxis indicated? Yes

Type prescribed: pharmacological and mechanical

Step 5 – signature

VTE risk assessment on admission

Signature A Connor, print name A Connor, date 11/10/22, time 08:30



#### Text:

Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place

Enoxaparin 40mg SC NOCTE 22.00

TEDS stocking TOP over 24 hours

Signed A Connors Prof no 7989321 bleep 4484

#### Regular non-injectable medication Farah Bibi Patient Name: \_ Check allergies/medicine sensitivities and patient identity H&C Number: 412 035 7027 DOB: 906 64 Prescribe anticoagulants/antiplatelets on page 3 only Day and month: 1/10 12/10 13/10 14/10 Circle times or enter variable dose/time Stop date 1000 NS NS NS Paraletamol Signature 1200 FP OR LO 1400 Supply Medicines Reconciliation (circle) Pre-admission Increased Decreased dose Gose Prof. no. 798 4321 (1800) NR FP DR 2200 Aconnors NS NS NS 4484 Ramipril 06∞ Stop date 1009 MOUD 10 ma PD MAINE 1400 Pre-addhission Increased Decreased New dose Prof. no. 1981 1800 0 2200 A COMMON Bleep 14485 Start date 0600 Frequency Stop date Dose 1000 1200 Signature Special instructions/Indication 1400 Supply Medicines Reconciliation (circle) Pre-admission Increased dose Decreased dose 1800 Prof. no. Pharmacist 2200 0600 Route Stop date 1000 1200 Special instructions/Indication 1400 0 Supply Medicines Reconciliation (circle) Pre-admission Increased Decreased dose Sign Prof. no. 1800 Pharmacist 2200 Start date 0600 Route Frequency Stop date 1000 Special instructions/Indication Signature 1200 1400 Supply Medicines Reconciliation (circle) Pre-admission Increased Decreased dose Ose Prof. no. 1800 Pharmacist 2200 Bleep 0600 Frequency Route Stop date 1000 1200 Signature Special instructions/Indication 1400 Supply Medicines Reconciliation (circle) Pre-admission Increased dose dose Sign Prof. no. 1800 Sign 2200

#### Text:

Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place


Regular non-injectable medication: Paracetamol 1g QID PO, Ramipril 10mg MANE OD ON HOLD.

Signed A Connors Prof no 7989321 bleep 4484

13

Oxygen section For use in adult patients (16 and over	·)		Patie H&C	nt Name Number	:_ Fi	2ml	n Bibi	DOB:_	ayı	e 64
A prescriber must prescribe the initial flow rate and of the method and rate of oxygen delivery should be all healthcare professionals in order to achieve the presc NB. The initial prescription does NOT need to be rew or flow rate is changed by the nurse or physiotherapi document the change in clinical notes. Remember, raclinical condition require medical review.	Itered by nu cribed satur ritten if the ist who mus	ation range. device t	be pre 88-920 ie. CO Is th	scribed % for t 2 retain	to achie hose at rates.  tient a	eve a ta isk of h	nic condit arget satu nypercapn	ration o	of 94-9 ratory	98% (or / failure
Prescription: OXYGEN		Administration round or other	n: Check r times s	and respecifies	cord flow	rate (FI	R)/device (	(D) at ea	ach m	edicine
Year: 2022 Day and mont Other time										
Continuous oxygen therapy	0600									
or 'When required' oxygen therapy	FR/D									
Target oxygen saturation 88-92% 4-98%	1000									
Other saturation range:	FR/D									
Tick here if saturation not indicated and state reason eg. end	1200									
of life care	FR/D									
Starting device and flow rate: Start date Stop date	1400									
2L NC 11 0 Signature	FR/D									
	1800									
Signature Prof. No.	FR/D									
7787321 Pharmacist	2200									
Print name ACONNOYS Bleep 4484	FR/D									
Guidance on administering oxygen thera vice (FR/D) at each drug round using the codes. Oxyge	<b>py</b> Nurse n saturation	es: Sign this pr s should be re	escriptio corded o	n chart n the p	on even	drug r	ound. Red	cord flow	w rate	and de-
A Air (not requiring O <sub>2</sub> , weaning or on PRN O <sub>2</sub> )	СР	Patient on CPAP	system	SM Sir	nple mask		If a ward	patient i	s requi	iring high
V24 Venturi 24% (change figure as appropriate for % in use)		Patient on NIV s	,			flow oxyg mask, cor				
N Nasal cannulae (eg. 2 litres via nasal specs, prescribe as '2		Other device (sp		reserve sure	acheostom		If target s	saturation	ns are	88-92%,
H28 Humidified oxygen at 28% (change figure as appropriate for			2000 A 40			,		oxygen (		specified

# Omitted doses of medicines coded 7 or delayed doses >2hrs



#### Text:

Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place

Oxygen section

Prescription: Oxygen

Year: 2022

Is this patient a known CO2 retainer? No

When required oxygen therapy

Target sats 94-98%

Starting device and flow rate 2litres NC

Start date 11/10

Signed A Connors Prof no 7989321 bleep 4484

As required medicatio	n	Famla Rihi	
Check allergies / medicine sensitivitie Check regular medicines		Patient Name: Farah 6161 H&C Number: 412 035 7027	DOB: 0190 64
Undansetron	art date		
4-8mg PONV BD	Time 24 hr 22-15		
Ibma	clock Dose Giny		
Pre-admission Increased Decreased dose dose New	Route // // Iarmacist Given W5/		5
Print A CONMIM Bleep 4494	by FR		
Dose Route Frequency Sto	Date 1/10 12/10		
Special instructions/ Indication	gnature Z4 hr clock 21.00 14-15		
Medicines Reconciliation (circle)	Dose 5my 5my/		
Sign Ol Prof. no. 7989 321 Ph	Given by FP		
Medicine D O O O O Sta	art date		
T.PMI NEB BID	op date Time gnature 24 hr		
. 010	clock Dose		
Pre-admission Increased Decreased dose dose New	Route Given		
Print A (NUM) S Bleep 4484   Medicine Sta	by art date		
Dose Route Frequency Ste	op date Time		
Special instructions/Indication Max dose in 24hrs Sig	gnature 24 hr clock		
Medicines Reconciliation (circle)  Pre-admission Increased Decreased dose dose New	Ipply Dose Route		
Sign Prof. no. Ph	Given by		
Medicine , Sta	art date Date		
	op date Time gnature 24 hr		
Special instructions/ introduction	clock Dose		
Pre-admission Increased Decreased dose dose New	Route		
Sign Prof. no. Ph Print Bleep	armacist Given by		
The state of the s	art date Date		
Dose Route Frequency Str	op date Time		
Special instructions/Indication Max dose in 24hrs Signature Max dose in 24hrs	gnature 24 hr clock		
Medicines Reconciliation (circle)	upply Dose		
Pre-admission Increased Decreased dose New	Route		
Print Bleep	Given by		

#### Text:

Patient: Farah Bibi, age 64, HCN 412 035 7027, 14 St Anne's Place

As required medication 0.9% NaCl 2.5ml NEB QID, Ondansetron 4-8mg PO/IV BD max 16mg in 24h, shortec 5mg 4-6 hourly PRN

Signed A Connors Prof no 7989321 bleep 4484

# Investigations

# **412 035 7027** BIBI, Farah (Female / 64 years)

# Complete Blood Count

Number	1	Ref. Range (Units)
Collected	14-Oct	
	2022	
	14:00	
Signed	D	
Source	BHSCT	
HGB	* 100	130-180 (g/L)
нст	* 0.30	0.40-0.54 (L/L)
WBC	*12.2	4.0-10.0 (x 10 <sup>9</sup> /L)
PLT	*100	150-450 (x 10 <sup>9</sup> /L)
RBC	* 3.2	3.8-5.8 (x 10 <sup>12</sup> /L)
MCV	* 71	76-100 (fL)
MCHC	* 300	320-360 (g/L)
MCH	* 25	27-32 (pg)
NEUT	*8.0	2.0-7.5 (x 10 <sup>9</sup> /L)
LYMPH	*3.8	1.0-3.5 (x 10 <sup>9</sup> /L)
MONO	0.3	0.2-0.8 (x 10 <sup>9</sup> /L)
EOSIN	0.06	0.04-0.4 (x 10 <sup>9</sup> /L)
BASO	0.01	0.01-0.1 (x 10 <sup>9</sup> /L)

#### \* Denotes abnormal result

# Electrolyte Profile

Number	1	Ref. Range (Units)
Collected	14-Oct	
	2022	
	14:00	
Signed	Ø	
Source	BHSCT	
Sodium	135	136-145 (mmol/L)
Potassium	4.1	3.5-5.3 (mmol/L)
Chloride	95	95-108 (mmol/L)
CO2	23	22-29 (mmol/L)
Urea	5.0	2.5-7.8 (mmol/L)
Creatinine	47	45-84 (μmol/L)
eGFR	>60	<60 (mL/min/1.73m <sup>2</sup> )

<sup>\*</sup> Denotes abnormal result

# Liver Profile

Number	1	Ref. Range (Units)
Collected	14-Oct	
	2022	
	14:00	
Signed	Ø	
Source	BHSCT	
T. Bilirubin	13	<21 (µmol/L)
ALP	58	30-130 (U/L)
AST	*40	<32 (U/L)
GGT	27	6-42 (U/L)
ALT	*35	<33 (U/L)
Albumin	40	35-50 mg/L

# CRP

Number	1	Ref. Range (Units)
Collected	14-Oct	
	2022	
	14:00	
Signed	D	
Source	BHSCT	
C reactive protein	*164	<5 (mg/L)
(CRP)		

# D dimer

Number	1	Ref. Range (Units)
Collected	14-Oct	
	2022	
	14:00	
Signed	D	
Source	BHSCT	
D dimer	*1.87	<0.5 (mg/L)

# NT pro-BNP

Number	1	Ref. Range (Units)
Collected	14-Oct	
	2022	
	14:00	
Signed	D	
Source	BHSCT	
NT pro-BNP	300	5-349 (pg/mL)


# Troponin T

Number	1	1	Ref. Range (Units)
Collected	14-Oct	14-Oct	
	2022	2022	
	14:00	15:00	
Signed	P	P	
Source	BHSCT	BHSCT	
Troponin T	9	9	0-14 (ng/L)


## ABG

Number	1	Ref. Range (Units)
Collected	14-Oct	
	2022	
	14:00	
Signed	D	
Source	BHSCT	
Sample type	Blood	
Blood type	Arterial	
Temperature	37.0°C	
FiO <sub>2</sub>	40%	
рН	*7.48	7.350-7.450
pCO2	*4.22	4.30-6.40 (kPa)
pO2	*7.9	11.00-14.40 (kPa)
Na⁺	135	133.0-146.0 (mmol/L)
K <sup>+</sup>	4.1	3.50-4.50 (mmol/L)
Cl <sup>-</sup>	95	95.0-108.0 (mmol/L)
Ca <sup>2+</sup>	1.3	1.150-1.350 (mmol/L)
Glu	6.7	4.0-7.7 (mmol/L)
Lac	*1.6	1.0-1.4 (mmol/L)
tHb	*100	115.0-180.0 (g/L)
Hct	*0.3	0.370-0.540 (%)
SO <sub>2</sub>	*92	94.0-98.0 (%)
BE	0.45	-2 - +3 (mmol/L)
cHCO₃	23.1	22.0-29.0 (mmol/L)

Case 1 Part 2 Facilitator Materials



Chest X-ray



# **ADDITIONAL FACILITATOR MATERIALS**

## Specialty Trainee Review

Insert G.P's Name and Address if not included on request letter or admission form	CLINICAL NOTES  ENTER FUI Name A Mr/G/Miss & B Address C Consultant & Ward/Clinic D Hospital No. E S.M. or W. D Date of Birth G Occupation H In-Patient Admn Date C: H  EACH ENTRY TO BE DATED AND SIGNED  Diagnosis  14/10/12  Thillan STS - Wareh C/V  14-15
IA HOSPITAL 1712 6BA	Aist re. chest pain + SDB  D3 Lap & hemisolectory  hudden onset about pain + SDB @ 13:15  Short pain & sided, pleintie, no radiation  Arror i SDB acutoly  Men cough pool of clear sputum  Low grade temp 37-7°C
ROYAL VICTORIA HOSPITAL BELFAST, BT12 6BA	A - Patent  B - RR 28 Spl, 92% on 40% Oz  Thing according murches  ABG TIRF  Depth founds at low Paly 8 on 40%  (XR - Basal  right DV)  C - Pubro 126 regular (RT <25 FCG-Simer Land)
Form No M 100 (R S 7)	BP 125/75  BP 125/75  Periph vedous  Part 2th: Input 2050ml  Doutput 3000ml  D- Hest PERIA  GCS 15/15  BM 6.9  E- 37.7°(  The concern re wound  The right of bleeding  Catheter during clar wins  WPH000273 Ravisod 1012  Karder - prophyladii clerare pr + green 0512147

#### Text:

**412 035 7027** BIBI, Farah (Female / 64 years)

14/10/22 14.15 Dillon ST5 urgent review

ATSP re. chest pain and SOB D3 lap R hemicolectomy

Sudden onset chest pain and SOB at 13.15. Chest pain R sided, pleuritic, no radiation. Associated with acute shortness of breath. New cough productive of clear sputum. Low grade temp 37.7.

O/E

A - Patent

B – RR 28, Sao2 92% on 40%v O2, using accessory muscles, chest examination – Reduced breath sounds at base, no crepitations, no signs of DVT.

ABG – Type 1 respiratory failure, PaO2 8 on 40% O2

CXR - basal atelectasis

C – pulse 126, regular, BP 125/75, CRT <2s, HS 1+2+0, no peripheral oedema, Past 24h Input 2950ml/Output 3000ml. ECG – sinus tachycardia, nil ischaemic change.

D - Alert, GCS 15/15, PERLA, BM 6.9

E – temp 37.7

Abdomen exam - no concern re wound

No signs of bleeding.

Catheter draining clear urine.

Kardex – prophylactic enoxaparin prescribed

last a grow Pl. In short a - 20=	-
Cont. Impresion Pluster doct pain ?PE ?LRTI/MAP	
- UZIV /PAV	. (
Plan: Higent bloods . (P) D dina, BNP, TaT, por	Dutimin
Monest CTPA - d/v ordiology	
Blood authors if temp spike	1
Smitim D+S	
Increase D2 to 60%	
Theoretic enoxaparin for ?PE	
merapenin enoxigaring it	
lover & IV Abx (pen allergie) for ? UKT	
Patient for excalation	7
Taten for breaking	
J. Dillon STS	
Jellon S15	
	r
	λ.
	-


Text:
Impression:
Pleuritic chest pain ?PE
?LRTI/HAP
Plan:
Urgent bloods, D dimer, BNP, TnT, procalcitonin
Urgent CTPA – discussed with radiology
Blood cultures if temp spike
Sputum O&S
Increase O2 to 60%
Therapeutic enoxaparin for ?PE
Cover with IV Abx (pen allergic) for ?LRTI
Continue input/output
Patient for escalation in event of further deterioration
Signed J Dillon ST5

Investigations CTPA Axial view



Left lower lob PE – axial view


## Coronal view



Left lower lob PE – coronal view

#### STUDENT MATERIALS

### **NEWS Observation Chart**




#### Text:

**412 035 7027** BIBI, Farah (Female / 64 years) 14/10/22

**NEWS Observation chart** 

0800 RR 20 /min. pulse 96/min BP 119/75. SaO2 94% on 1INC. Temp 36.9. Alert. NEWS 4
1200 RR 22/min pulse 96/min BP 127/78. SaO2 94% on 2l. Temp 37.1 Alert. NEWS 5
1300 RR 24/min, pulse 109, BP 129/80, SaO2 92% on 4l NC, temp 37.2. Alert. NEWS 7
13.30 - RR 30 /min. pulse 126/min BP 130/80. SaO2 92% on 40%v O2. Temp 37.5, Alert. NEWS 9
13.45 - RR 30/min, pulse 129, BP 135/85, SaO2 93% on 40%, temp 37.2 Alert. NEWS 9
14.00 - RR 28/min, pulse 126, BP 125/75, SaO2 92% on 40%, temp 37.7. Alert. NEWS 9
14.15 - RR 30/min, pulse 125, BP 120/75, SaO2 92% on 60%, temp 37.6. Alert. NEWS 9
Patient at radiology

14.45 - RR 32/min, pulse 140, BP 110/69, SaO2 92% on 98% humidified, 37.5. Alert. NEWS 11



Text:				
Clinical Response to NEWS Triggers				
NEWS score				
0				
Frequency of monitoring Minimum 12 hourly				
Clinical response (Variance with response must be documented)				
Continue routine NEWS monitoring with every set of observations.				
Total: 1 – 2	Total: 3-4			
Frequency of monitoring Minimum 6 hourly	Minimum 4 hourly			
Clinical response Inform registered nurse who must assess the patient				
Registered nurse to decide if increased frequency of monitoring and/or escalation of clinical care i required.				
NEWS of 4 or more? THINK SEPSIS				
Total: 3 in one parameter	Total: 5 or more			
Frequency of monitoring – Increased frequency to a minimum of 1 hourly				
Clinical response Registered nurse to urgently inform the medical team caring for the patient (and Critical Care Outreach Team (CCOT) on RVH site only)				
Urgent assessment by medical team caring for the patient				
Check for other adverse signs eg. Oliguria				
Consider fluid balance chart.				
NEWS of 4 or more? THINK SEPSIS				
Total: 7 or more				
Frequency of monitoring Continuous monitoring of vita	l signs, Minimum of half hourly recording			
Clinical response Registered nurse to immediately inform the medical team caring for the patient at least Specialist Registrar or above (and CCOT on RVH site only)				
Immediate response required (if peri-arrest call 6666).				
NEWS of 4 or more? THINK SEPSIS				

49

Call medical team caring for the patient if you have any concerns about the patient regardless of the

NEWS score

**Sepsis Screening Tool** 

Are any two of the following SIRS\* criteria present? Respiratory rate: >20/min,Temperature: <36 or >38.30C, Heart rate: >90 bpm, WCC or <4x109/L

If YES patient has SIRS

Does your patient also have a history or signs suggestive of a new infection?

For example: Cough/sputum/chest pain, Abdo pain/distension/diarrhoea, Line infection, Cellulitis/wound infection/septic, arthritis, Dysuria, headache with neck stiffness, Endocarditis

If YES patient has SEPSIS

Treat for SEPSIS

Sepsis six bundle within one hour

Highflow 02, Blood cultures, IV antibiotics, IV fluids, Lactate, Urine output

Reassess for severe SEPSIS; any signs of organ dysfunction

For example: Hypotension, Unexplained coagulopathy, High Lactate, Renal dysfunction, Unexplained altered mental state

If YES: patient has severe sepsis

Pain score

O = No pain, 10 = Worst imaginable

Nausea score

O = No nausea, 1 = Mild nausea, 2 = Severe nausea, 3 = Vomiting

\*SIRS = Systemic Inflammatory Response Syndrome

Guidance on administering oxygen therapy Nurses: Sign this prescription chart on every drug round. Record flow rate and device at each drug round using the codes. Oxygen saturations should be recorded on the patient's observation cart.

A Air, CP CPAP system, SM Simple Mask, V24 Venturi 24% (change figure for % use), NIV NIVE system, RM Reservoir mask, N Nasal cannulae, OTH Other, TM Tracheostomy mask, H28 Humidified oxygen 28% (change figure as appropriate), HFNO (High Flow Nasal Oxygen)

If a ward patient is requiring high flow oxygen via non rebreathe mask, consider medical review.

If target saturations are 88-92%, nebulised drugs should not be driven by oxygen (unless specified by the doctor).